Skip to main content

Table 1 Patients’ characteristic

From: It’s never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial

 

Intention-to-treat

Per-protocol

All

N = 41

IG vs. CG

P

IG

N = 18

CG

N = 19

All

N = 37

IG vs. CG

P

Age

 median (range)

62 (44 – 82)

0.025

70 (44 – 82)

60 (46 – 75)

63 (44 – 82)

0.026

Sex

 m:f N (%)

11 (27): 30 (73)

 

4 (22): 14 (78)

7 (37): 12 (63)

11 (30): 26 (70)

 

BMI

 median (range)

25 (19 – 42)

0.375

25 (19 – 42)

24 (21 – 31)

24 (19 – 42)

0.425

Diagnosis N (%)

 Breast cancer

14 (34)

 

8 (44)

4 (21)

12 (32)

 

 Colorectal cancer

14 (34)

 

3 (17)

10 (53)

13 (35)

 

 Gynecological cancer other than breast

4 (10)

 

2 (11)

1 (5)

3 (8)

 

 Upper gastrointestinal cancer

2 (5)

 

1 (6)

1 (5)

2 (5)

 

 Non-small cell lung cancer

1 (2)

 

0 (0)

1 (5)

1 (3)

 

 Non-Hodgkin’s lymphoma

5 (12)

 

4 (22)

1 (5)

5 (14)

 

 Multiple myeloma

1 (2)

 

0 (0)

1 (5)

1 (3)

 

Therapies N (%)

 Surgery

38 (93)

 

16 (89)

18 (95)

34 (92)

 

 Radiation

15 (37)

 

8 (44)

5 (26)

13 (35)

 

 Hematopoietic cell transplantation

2 (5)

 

1 (6)

1 (5)

2 (5)

 

 Chemotherapy

41 (100)

 

18 (100)

19 (100)

37 (100)

 

   N cycles, median (range)

6 (1 – 18)

0.681

6 (2 – 6)

6 (2 – 16)

6 (2 – 16)

0.775

   N neurotoxic agents, median (range)

2 (1 – 4)

0.115

2 (1 – 4)

1 (1 – 4)

2 (1 – 4)

0.061

   Therapy-free weeks, median (range)

11 (1 – 167)

0.754

10 (1 – 167)

18 (3 – 98)

13 (1 – 167)

0.775

CIPN symptoms N (%)

  Reduced vibration sense*

28 (70)

 

13 (77)

13 (68)

26 (72)

 

  Reduced joint position sense#

11 (28)

 

5 (29)

6 (32)

11 (31)

 

  Reduced temperature sensation†

23 (58)

 

12 (71)

10 (53)

20 (56)

 

  Reduced pain sensation†

4 (10)

 

2 (12)

2 (11)

4 (11)

 

  Loss of reflexes ASR / PSR

28 (68) / 8 (20)

 

12 (67) / 3 (17)

13 (68) / 3 (16)

25 (68) / 6 (16)

 

Compliance %, median (range)

92 (25 – 100)

0.175

92 (71 – 100)

100 (71 – 100)

96 (71 – 100)

0.118

  1. *measured on the first metacarpophalangeal joint, value < 5 (scale 0–8); #measured on second toe, ≥ 3 failures out of 10 trials in random order; †measured on arch, ≥ 3 failures out of 10 trials in random order; bold type indicates significance P<0.05
  2. Abbreviations: ASR Achilles tendon reflex, PSR patellar tendon reflex, IG intervention group, CG control group, BMI body mass index, CIPM chemotherapy-induced peripheral neuropathy
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us